OBJECTIVE: Patients with rheumatoid arthritis (RA) have an increased risk of coronary heart disease (CHD). Some RA therapies may modify this risk, but the underlying mechanisms are unclear. The cholesterol efflux capacity of high-density lipoprotein (HDL) is associated with a reduced CHD risk in non-RA populations; however, inflammation may impair the function of HDL. The aim of this study was to evaluate whether reduced inflammation resulting from treatment with methotrexate (MTX), adalimumab (ADA), or tocilizumab (TCZ) would increase the net cholesterol efflux capacity of HDL in patients with RA. METHODS: A longitudinal multicenter study repository (Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository) provided clinical information for and serum samples from 70 patients with RA before and 6 months after starting treatment with a new drug (MTX [n = 23], ADA [n = 22], or TCZ [n = 25]). Disease activity was measured using the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR). The net cholesterol efflux capacity was measured in paired serum samples using THP-1 macrophages, and total cellular cholesterol was measured by fluorometric assay. RESULTS: The DAS28-ESR decreased with all treatments (P < 0.001). Net cholesterol efflux capacity was not significantly changed after 6 months of new RA therapy (mean ± SD 36.9 ± 17.3% units at baseline versus 38.0% ± 16.9% units at 6 months [P = 0.58]). However, change in net cholesterol efflux capacity was associated with change in the DAS28-ESR (ρ = -0.25, P = 0.04). In a post hoc analysis of patients with impaired net cholesterol efflux capacity at baseline, treatment with TCZ resulted in significant improvement in net cholesterol efflux capacity (21.9 ± 14.7% units at baseline versus 31.3% ± 12.8% units at 6 months [P < 0.02]), but this was not observed with MTX or ADA. CONCLUSION: Net cholesterol efflux capacity of HDL cholesterol did not change significantly after 6 months of new RA therapy, except in patients with impaired baseline cholesterol efflux capacity who were receiving TCZ. Change in disease activity was associated with change in the net cholesterol efflux capacity.
OBJECTIVE:Patients with rheumatoid arthritis (RA) have an increased risk of coronary heart disease (CHD). Some RA therapies may modify this risk, but the underlying mechanisms are unclear. The cholesterol efflux capacity of high-density lipoprotein (HDL) is associated with a reduced CHD risk in non-RA populations; however, inflammation may impair the function of HDL. The aim of this study was to evaluate whether reduced inflammation resulting from treatment with methotrexate (MTX), adalimumab (ADA), or tocilizumab (TCZ) would increase the net cholesterol efflux capacity of HDL in patients with RA. METHODS: A longitudinal multicenter study repository (Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository) provided clinical information for and serum samples from 70 patients with RA before and 6 months after starting treatment with a new drug (MTX [n = 23], ADA [n = 22], or TCZ [n = 25]). Disease activity was measured using the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR). The net cholesterol efflux capacity was measured in paired serum samples using THP-1 macrophages, and total cellular cholesterol was measured by fluorometric assay. RESULTS: The DAS28-ESR decreased with all treatments (P < 0.001). Net cholesterol efflux capacity was not significantly changed after 6 months of new RA therapy (mean ± SD 36.9 ± 17.3% units at baseline versus 38.0% ± 16.9% units at 6 months [P = 0.58]). However, change in net cholesterol efflux capacity was associated with change in the DAS28-ESR (ρ = -0.25, P = 0.04). In a post hoc analysis of patients with impaired net cholesterol efflux capacity at baseline, treatment with TCZ resulted in significant improvement in net cholesterol efflux capacity (21.9 ± 14.7% units at baseline versus 31.3% ± 12.8% units at 6 months [P < 0.02]), but this was not observed with MTX or ADA. CONCLUSION: Net cholesterol efflux capacity of HDL cholesterol did not change significantly after 6 months of new RA therapy, except in patients with impaired baseline cholesterol efflux capacity who were receiving TCZ. Change in disease activity was associated with change in the net cholesterol efflux capacity.
Authors: Christina Charles-Schoeman; Yuen Yin Lee; Victor Grijalva; Sogol Amjadi; John FitzGerald; Veena K Ranganath; Mihaela Taylor; Maureen McMahon; Harold E Paulus; Srinivasa T Reddy Journal: Ann Rheum Dis Date: 2012-01-20 Impact factor: 19.103
Authors: Anand Rohatgi; Amit Khera; Jarett D Berry; Edward G Givens; Colby R Ayers; Kyle E Wedin; Ian J Neeland; Ivan S Yuhanna; Daniel R Rader; James A de Lemos; Philip W Shaul Journal: N Engl J Med Date: 2014-11-18 Impact factor: 91.245
Authors: Suguru Yamamoto; Patricia G Yancey; T Alp Ikizler; W Gray Jerome; Ryohei Kaseda; Brian Cox; Aihua Bian; Ayumi Shintani; Agnes B Fogo; Macrae F Linton; Sergio Fazio; Valentina Kon Journal: J Am Coll Cardiol Date: 2012-11-07 Impact factor: 24.094
Authors: Christina Charles-Schoeman; Junji Watanabe; Yuen Yin Lee; Daniel E Furst; Sogol Amjadi; David Elashoff; Grace Park; Maureen McMahon; Harold E Paulus; Alan M Fogelman; Srinivasa T Reddy Journal: Arthritis Rheum Date: 2009-10
Authors: Katherine P Liao; Martin P Playford; Michelle Frits; Jonathan S Coblyn; Christine Iannaccone; Michael E Weinblatt; Nancy S Shadick; Nehal N Mehta Journal: J Am Heart Assoc Date: 2015-01-30 Impact factor: 5.501
Authors: Kevin W Byram; Annette M Oeser; MacRae F Linton; Sergio Fazio; C Michael Stein; Michelle J Ormseth Journal: J Clin Rheumatol Date: 2018-12 Impact factor: 3.517
Authors: Michelle J Ormseth; Patricia G Yancey; Suguru Yamamoto; Annette M Oeser; Tebeb Gebretsadik; Ayumi Shintani; MacRae F Linton; Sergio Fazio; Sean S Davies; L Jackson Roberts; Kasey C Vickers; Paolo Raggi; Valentina Kon; C Michael Stein Journal: IJC Metab Endocr Date: 2016-08-28
Authors: Adriana M Hung; Yohei Tsuchida; Kristen L Nowak; Sudipa Sarkar; Michel Chonchol; Victoria Whitfield; Natjalie Salas; Anna Dikalova; Patricia G Yancey; Jiansheng Huang; MacRae F Linton; T Alp Ikizler; Valentina Kon Journal: Clin J Am Soc Nephrol Date: 2019-04-23 Impact factor: 8.237
Authors: G V Papamichail; T E Markatseli; A N Georgiadis; V G Xydis; H Milionis; A A Drosos; P V Voulgari Journal: Heart Vessels Date: 2022-06-24 Impact factor: 1.814
Authors: Michelle J Ormseth; Qiong Wu; Shilin Zhao; Ryan M Allen; Joseph Solus; Quanhu Sheng; Yan Guo; Fei Ye; Marisol Ramirez-Solano; S Louis Bridges; Jeffrey R Curtis; Kasey Vickers; C Michael Stein Journal: Ann Rheum Dis Date: 2020-09-21 Impact factor: 19.103
Authors: R Kaseda; Y Tsuchida; J L Gamboa; J Zhong; L Zhang; H Yang; A Dikalova; A Bian; S Davies; A F Fogo; M F Linton; N J Brown; T A Ikizler; V Kon Journal: Nutr Metab Cardiovasc Dis Date: 2018-03-08 Impact factor: 4.222